Filip Forsberg, Giannis Antetokounmpo Join Nashville Soccer Club Ownership Group
2.3.2023 17:00:00 EET | Business Wire | Press release
As Nashville Soccer Club enters its fourth season in Major League Soccer, and second at GEODIS Park, principal owner John Ingram announced today that leading scorer in Nashville Predator history Filip Forsberg and two-time MVP and NBA Champion Giannis Antetokounmpo have joined the team’s ownership group.
Antetokounmpo is joined in ownership by his brothers Thanasis, Kostas and Alex as well – all of whom play professional basketball worldwide. Thanasis joined Giannis in winning the NBA Championship with the Milwaukee Bucks in 2021, and Kostas won one with the Los Angeles Lakers in 2020.
The announcement of the new owners continues the strong momentum built by Nashville SC in the lead-up to the 2023 season, highlighted by its 'Man in Black’ jersey collaboration with the Estate of Johnny Cash. That momentum continued with a 2-0 victory over New York City FC in front of 28,051 fans at GEODIS Park this past Saturday.
Forsberg and Antetokounmpo join a robust and diverse ownership group whose most recent additions include Reese Witherspoon, her husband Jim Toth and Derrick Henry.
“Nashville is the best sports city in the country, and I am extremely blessed to now be involved with two of our pro teams,” said Forsberg. “Our city is one big family and fanbase, and we support each other on and off the field. Nashville SC has been such a great addition to our sports culture, and joining the ownership group was an opportunity I wasn’t going to pass up. I grew up a Liverpool FC fan in Sweden, and after today I am happy to add a second set of colors to cheer for!”
“My father was a professional soccer player, and it was the first sport I fell in love with in Greece,” said Antetokounmpo. “I’ve always had the dream of owning a soccer team. When my brothers and I explored Nashville SC, we knew it was a team and a city that we wanted to get involved with. I couldn’t be more excited to join the Boys in Gold, and can’t wait to come to a match at GEODIS Park soon!”
“Soccer is a global sport, and our newest owners once again reinforce our club’s commitment to being a global team,” said Ingram. “Filip and Giannis are not just amazing athletes – they are ambassadors for their respective sports, role models for millions and advocates in their hometowns and worldwide. We share a common belief that our teams not only play to the highest standards, but also lift up their communities and help those who need it most.”
Nashville SC takes on the road to face the New York Red Bulls at 6:30 p.m. CT on Saturday, March 4. Fans ns can follow the action on the MLS Season Pass on the Apple TV app and the club on its digital and social channels on Instagram, Facebook, TikTok, Twitter and Spotify.
MEDIA RESOURCES:
- Nashville SC Media Center with news, b-roll from training, match notes, other video and photo resources
- Media looking to follow NSC on social media can find the club on TikTok, Twitter and Instagram with the handle @NashvilleSC. For Facebook and YouTube please use “Nashville Soccer Club”
- The official club hashtag when referring to Nashville SC on social media is #EveryoneN
FOR MORE INFORMATION, CONTACT: Zach Hunt, zach@tsgnashville.com, 615.321.3110.
About Nashville SC
Nashville SC joined Major League Soccer on Feb. 29, 2020 in front of the largest attendance ever recorded for a soccer match in the State of Tennessee. In its inaugural MLS season, Nashville SC defeated expectations by becoming the second MLS expansion side to win and advance to the Conference Semifinals in the 2020 Audi MLS Cup Playoffs. Nashville SC returned to the 2021 Audi MLS Cup Playoffs in its sophomore season after becoming just the seventh team in MLS history to go unbeaten at home in a season. Nashville SC inaugurated GEODIS Park, the largest soccer-specific stadium in the United States and Canada, in front of a 30,109-sellout crowd on May 1, 2022. For more information, visit NashvilleSC.com and follow the club at @NashvilleSC on Instagram , Facebook , Twitter and Spotify .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005537/en/
Contact information
Zach Hunt, zach@tsgnashville.com, 615.321.3110
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom